FINWIRES · TerminalLIVE
FINWIRES

BeOne Medicines Receives US FDA Priority Review for Tevimbra Combination Therapy

By

BeOne Medicines' (ONC) supplemental biologics license application for Tevimbra, in combination with Ziihera and chemotherapy, was granted priority review designation by the US Food and Drug Administration, the company said Wednesday.

This drug is for patients with a specific type of stomach or throat cancer that has spread or cannot be removed by surgery. It specifically targets tumors that test positive for a protein called HER2, which helps the cancer grow.

Interim data from a phase 3 trial of the combination therapy supported the application, with the Tevimbra combination demonstrating statistically significant improvement in overall survival and progression-free survival, the company said.

The combination therapy's safety findings in the trial were generally consistent with the component's known effects, BeOne Medicines added.

Price: $296.42, Change: $-1.74, Percent Change: -0.58%

Related Articles

Wire

Brown-Forman, Pernod Ricard End Talks on Potential Combination

Brown-Forman (BF.A) and Pernod Ricard ended discussions over a potential business combination after failing to reach mutually agreeable terms."We intend to create long-term value for all stakeholders by focusing on our strategic and operational priorities," Brown-Forman said Tuesday in a statement. "This includes unlocking future growth by expanding our geographic footprint, continuing to build brands that resonate with consumers, and enhancing operational efficiency."In late March, the companies confirmed they were in talks, noting "there could be no assurance that any such agreement would be reached."Brown-Forman shares fell 2.9% in after-hours trading.

$BF.A$BF.B
Wire

Update: Visa Fiscal Q2 Adjusted Earnings, Revenue Rise

(Updates with share repurchase and dividend information in the last two paragraphs.)Visa (V) reported fiscal Q2 adjusted earnings late Tuesday of $3.31 per diluted share, up from $2.76 a year earlier.Analysts polled by FactSet expected $3.10.Revenue for the three months ended March 31 was $11.23 billion, up from $9.59 billion a year earlier.Analysts polled by FactSet expected $10.75 billion.In April, the company's board authorized a new $20 billion multi-year share repurchase program, it said.Visa also maintained its quarterly dividend at $0.67 per share, payable June 1 to holders on record as of May 12.

$V
Wire

BXP Q1 FFO Falls, Revenue Rises; Shares Drop After Hours

BXP Inc (BXP) reported Q1 funds from operations late Tuesday of $1.59 per diluted share, down from $1.64 a year earlier.Analysts surveyed by FactSet expected $1.58.Revenue in the three months ended March 31 rose to $872.1 million from $865.2 million a year earlier.Analysts polled by FactSet expected $843.1 million.The company expects FFO of $1.69 to $1.71 a share in Q2 and $6.90 to $7.04 a share in the full year, compared with the prior forecast of $6.88 to $7.04.Analysts surveyed by FactSet expect $1.72 in Q2 and $6.95 in the full year.BXP shares fell 4.6% in after-hours trading.

$BXP